<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03010631</url>
  </required_header>
  <id_info>
    <org_study_id>SCMP-0211-304</org_study_id>
    <nct_id>NCT03010631</nct_id>
  </id_info>
  <brief_title>Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers</brief_title>
  <official_title>Comparative Pharmacokinetics and Food-Effect Bioavailability of a Sprinkle Formulation of Lubiprostone After Oral Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sucampo AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sucampo Pharma Americas, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sucampo Pharma Americas, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to compare the pharmacokinetics and food-effect bioavailability of lubiprostone
      sprinkle in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the pharmacokinetics of the sprinkle formulation of lubiprostone, as compared to
      lubiprostone capsules and to determine the effect of food on the bioavailability and plasma
      pharmacokinetics of lubiprostone sprinkle.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) from hour 0 to the last measurable concentration (AUC0-t) of M3 metabolite for sprinkle formulation compared to capsule lubiprostone</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of M3 metabolite for sprinkle formulation compared to capsule lubiprostone</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total exposure (AUC) of M3 with administration of sprinkle lubiprostone under fed vs. fasted condition</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak exposure (Cmax) of M3 with administration of sprinkle lubiprostone under fed vs. fasted condition</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence rates of adverse events with sprinkle and capsule administration</measure>
    <time_frame>2 weeks</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>48 mcg lubiprostone capsule once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1- Crossover</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>48 mcg lubiprostone sprinkle once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>48 mcg lubiprostone sprinkle once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2- Crossover</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>48 mcg lubiprostone sprinkle once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lubiprostone Capsule</intervention_name>
    <description>48 mcg of capsule administered once orally under fasted condition</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Amitiza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lubiprostone Sprinkle Formulation</intervention_name>
    <description>48 mcg of sprinkle formulation administered once orally under fasted condition</description>
    <arm_group_label>Cohort 1- Crossover</arm_group_label>
    <other_name>Amitiza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lubiprostone Sprinkle Formulation</intervention_name>
    <description>48 mcg of sprinkle formulation administered once orally under fasted condition</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Amitiza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lubiprostone Sprinkle Formulation</intervention_name>
    <description>48 mcg of sprinkle formulation administered once orally under fed condition</description>
    <arm_group_label>Cohort 2- Crossover</arm_group_label>
    <other_name>Amitiza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female, between 18 and 55 years of age, inclusive.

          -  Subject has a 12-lead electrocardiogram (ECG) within normal limits and is in good
             health based upon review of medical history, physical examination results, vital signs
             (within normal range), and normal laboratory profile for both blood and urine.

        Exclusion Criteria:

          -  Subject has an active or recent history of alcoholism or drug addiction (within 1 year
             prior)

          -  Subject is a smoker or has a recent history of smoking (within 6 months)

          -  Subject routinely consumes food known to alter drug metabolism (i.e., grapefruit
             juice, coffee, tea, cola, chocolate, cocoa, or other caffeine or methyl-xanthine
             containing foods or beverages) and/or cannot refrain from these items

          -  Subject has donated blood within 3 months

          -  Subject has a medical/surgical condition that might interfere with the absorption,
             distribution, metabolism, or excretion of the study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cassandra Key, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICON Early Phase Services, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICON</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2016</study_first_submitted>
  <study_first_submitted_qc>January 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <disposition_first_submitted>March 22, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 26, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 29, 2018</disposition_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubiprostone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

